Physician profile
Danielle Cincinelli
NPI 1306091152
$7,990.51
in general payments reported to CMS, 2019-2025
24 companies · $1,960 in 2025
The $1,960 reported for 2025 was more than what 93% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,632 · 2022: $1,348 · 2023: $1,756 · 2024: $1,295 · 2025: $1,960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,546 · Education: $464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,546.16 |
| Education | $463.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,159.91 | 2021-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Heartmate Touch |
| Actelion Pharmaceuticals US, INC. | $895.90 | 2023-2025 | Uptravi, Opsumit |
| Astrazeneca Pharmaceuticals LP | $796.20 | 2021-2025 | Farxiga, Wainua |
| Novartis Pharmaceuticals Corporation | $642.30 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $610.40 | 2021-2025 | Jardiance |
| Impulse Dynamics (USA) INC. | $511.56 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $397.76 | 2022-2025 | Amvuttra |
| Bayer Healthcare Pharmaceuticals INC. | $363.07 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $315.38 | 2023-2024 | Lifevest |
| Pfizer INC. | $284.83 | 2021-2025 | |
| Scpharmaceuticals INC. | $270.27 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $138.64 | 2022-2025 | Verquvo, Winrevair, Capvaxive |
| United Therapeutics Corporation | $101.63 | 2025 | Tyvaso, Orenitram, Remodulin |
| Vifor Pharma, INC. | $78.00 | 2021-2023 | Veltassa |
| Novo Nordisk INC | $67.71 | 2022-2025 | Ozempic, Rybelsus |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akcea Therapeutics, INC. | $62.76 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $59.25 | 2025 | Eliquis |
| Bridgebio Pharma, INC. | $56.99 | 2025 | Attruby |
| Kestra Medical Technology Services, INC. | $50.61 | 2022 | |
| Abiomed | $48.75 | 2025 | |
| Daxor Corporation | $25.27 | 2023 | Bva-100 |
| Daiichi Sankyo INC. | $20.37 | 2023 | Injectafer |
| Lexicon Pharmaceuticals, INC. | $19.92 | 2023 | Inpefa |
| Janssen Pharmaceuticals, INC | $13.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Cincinelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.